Consequently, FGFR1 inhibition with the pan-FGFR TKI LY2874455 led to palbociclib resensitization, suggesting the combinatorial inhibition of CDK4/6 with FGFR1 may be a promising strategy for the treatment of KRAS-mutant NSCLC [70]. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.